It was observed that the number of MVs decreased significantly at 6, 12, and 24 months after treatment in all evaluated populations compared to pre-treatment (Figure 5), except for MVs related to tumor cells (HER2+ and HSP27+) (Figure S3). The gene discussed is ERBB2; the disease is neoplasm.